Point Of Care Infectious Disease Diagnostics Testing Market: Market Size & Forecast 2026

Point-of-care (POC) infectious disease diagnostics refers to medical testing performed outside traditional laboratory settings, at clinics, hospitals, pharmacies, and even at-home, delivering results in minutes rather than days. The market spans technologies including lateral flow immunoassays, molecular POC platforms, and electrochemical sensors, covering disease areas such as HIV, influenza, COVID-19, malaria, tuberculosis, hepatitis, and sexually transmitted infections. With a 2025 market value of approximately $18.2 billion, this segment represents a critical component of the broader in-vitro diagnostics industry.

• •Encompasses rapid immunoassays, molecular POC platforms, and biosensor-based tests
• •Covers major infectious diseases including HIV, influenza, TB, COVID-19, hepatitis, and STIs
• •Results delivered in minutes to hours, enabling immediate clinical decisions

The continued expansion of the POC infectious disease diagnostics market is fueled by several macro and micro-level factors. The global burden of infectious diseases, particularly in low- and middle-income countries, drives sustained demand for affordable, accessible rapid tests. Advances in molecular POC technology, such as isothermal amplification and microfluidic cartridges, are improving test sensitivity and multiplexing capabilities. Additionally, lessons from the COVID-19 pandemic accelerated regulatory pathways and investment in decentralized testing infrastructure worldwide.

• •Rising global prevalence of infectious diseases and antimicrobial resistance concerns
• •Technological improvements in molecular POC, biosensors, and connectivity-enabled devices
• •Post-pandemic infrastructure and regulatory momentum supporting decentralized testing

By technology, the market is broadly segmented into lateral flow assays (rapid tests), molecular diagnostics, and electrochemical/other technologies, with lateral flow remaining the largest segment by volume. By disease type, infectious disease testing covers HIV, influenza, malaria, TB, hepatitis, COVID-19, and other STIs. Geographically, North America and Europe lead in market value due to advanced healthcare infrastructure and high per-capita spending, while Asia-Pacific is the fastest-growing region driven by large populations, rising healthcare access, and increasing government investment in diagnostics.

• •Lateral flow assays dominate by volume; molecular POC is the fastest-growing technology segment
• •North America holds the largest market share; Asia-Pacific is the fastest-growing region
• •Key disease areas include HIV, influenza, TB, hepatitis, and COVID-19 testing

What are the recent trends and outlook?

Looking ahead, the market is shaped by several emerging trends: the convergence of POC testing with digital health platforms and telemedicine, enabling connected devices that transmit results in real time to care teams. Multiplex POC panels capable of detecting multiple pathogens from a single sample are gaining clinical adoption. Expanding test menus for antimicrobial resistance and emerging infectious diseases are opening new application areas. While the growth rate of approximately 7.5% CAGR reflects a maturing market rather than explosive expansion, the long-term outlook remains positive as healthcare systems globally prioritize early diagnosis, patient-centric care models, and pandemic preparedness.

• •Integration with digital health and telemedicine platforms is accelerating connected POC adoption
• •Multiplex POC panels and expanded antimicrobial resistance testing are key innovation frontiers
• •Long-term outlook remains positive, supported by decentralized care models and pandemic preparedness priorities